[Market Feature] HEM Pharma Hits Record High on News of Leading Production in Amway's New Project
HEM Pharma is showing strong performance in early trading.
As of 9:03 a.m. on December 2, HEM Pharma was trading at 53,600 won, up 8.28% (4,100 won) from the previous day. At one point, it rose to 54,500 won, marking a new 52-week high.
Investor sentiment has been boosted by news that the company will lead production in a new probiotics development project spearheaded by Amway's Nutrilite brand. This project is a new global product that maximizes gut health benefits by combining HEM Pharma's newly developed strains with plant-derived ingredients from Amway's farms.
Hot Picks Today
"Is This Serious? Should I Go Back to Korea?"... New U.S. Internship Guidelines Put International Students on Edge
- "South Korea Excels" Even Mongolians, Renowned for Good Eyesight, Flock In... Chinese Spend 57.7 Billion, Japanese 28.5 Billion on K-Medical
- Lee Jaemyung Congratulates on Childbirth: 1990-Born Yong Hyein Nominated as Minister of Gender Equality and Family [Profile]
- European Museum Hit by Another Daylight Robbery... Thieves Boldly Entered With Tickets
- Actress Runs 100km Marathon in Sweltering Heat for Daughter With Rare Disease... TV Show Faces Criticism for "Enforced Emotion" [Sunday Culture]
HEM Pharma has completed all technical verification procedures between Korea and the United States, including an on-site inspection of its Sejong plant and a review of test reports, in collaboration with Amway's global headquarters. Having secured technical feasibility and supply chain reliability at the pilot stage, the company expects to accelerate its global market expansion going forward.
![[Market Feature] HEM Pharma Hits Record High on News of Leading Production in Amway's New Project](http://www.asiae.co.kr/news/img_view.htm?img=2025120109182037469_1764548300.jpg)
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
